Navigation Links
Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
Date:4/17/2010

MM-121 studies in breast cancer models and xenograft response prediction. MM-111 breast cancer study in combination with trastuzumab.

Cambridge, MA (PRWEB) April 17, 2010 -- Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the company’s pipeline of five novel cancer antibodies, at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held April 17 – 21, 2010, in Washington, D.C.

MM-121
Two posters will show pre-clinical data on MM-121, a monoclonal antibody designed to block signaling of the ErbB3 receptor. The ErbB receptor family has been known for years to have an impact on cancer signaling. Merrimack gained insight into the critical role of the ErbB3 receptor in cancer biology through the use of their Network Biology platform that led to the novel design of MM-121.

Poster 1806 shows pre-clinical data on MM-121’s efficacy as a single agent, and in combination with tamoxifen and paclitaxel, in ER+ and triple negative breast cancer studies.

Title: Efficacy of MM-121 in ER+ and triple negative breast cancer studies
Poster Session: Clinical Research 7
Number: 1806
Date/Time: Monday April 19, 2010 9:00 AM - 12:00 PM
Location: Exhibit Hall A-C, Poster Section 32 Permanent Abstract


MM-121
Poster 3756 shows pre-clinical data on efforts to derive a predictive biomarker signature that identifies tumors responsive to MM-121.

Title: Prediction of xenograft response to MM-121, an anti-ErbB3 inhibitor, using computational modeling and measurements of five biomarkers
Poster Session: Clinical Research 13
Number: 3756
Date/Time: Tuesday April 20, 2010 9:00 AM - 12:00 PM
Location: Exhibit Hall A-C, Poster Section 33


MM-111
MM-111 is a bispec
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
2. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
3. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
4. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
5. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
6. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
7. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
8. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
9. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
10. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
11. Zimmer Holdings to Present at Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 This ... PHA, PBS, Starch Based Plastics, Regenerated Cellulose, PCL), ... Global Trends and Forecasts to 2019”, defines and ... analysis and forecast of its global volume and ... 54 Figures spread through 178 Slides and in-depth ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in minimally ... that its Board of Directors has appointed Dr. ... and member of the Board effective immediately. In ... responsibilities within the company, including further developing the ... manufacturing and finance. , Dr. Carol joined ...
(Date:10/25/2014)... 25, 2014 Berkshire Corporation, the ... to announce the release of the ValuSeal® IonX™ ... of contamination containment in critical processing applications. , ... higher cleanroom environments, ValuSeal® IonX™ is a laser ... wiper that continues Berkshire’s innovative focus on meeting ...
(Date:10/25/2014)... and NEW YORK ... Inc. (OTCQB: ACCPD), formerly Access Pharmaceuticals, Inc. (ACCP), ... areas, announced it has implemented a 1-for-50 reverse ... opening of trading on Friday, October 24, 2014. ... basis under new CUSIP number 72754H109 and temporary ...
Breaking Biology Technology:Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2
... 5:00 p.m. U.S. EDT , , FRAZER, Pa., ... quarterly earnings conference call covering second quarter 2009 results for 5:00 p.m. EDT on ... , , 4:10 p.m. EDT Q2 2009 ... To participate in the conference call, dial 913-312-0379, ...
... June 30 Hospira, Inc. (NYSE: HSP ... today announced agreements with MedAssets on intravenous (I.V.) solutions ... agreement for infusion devices. The five-year MedAssets agreements are ... and equipment, and July 1, 2009, for infusion devices. ...
... needs, clinical uses and funding sources , , ROCKVILLE, ... in Rockville, Md., announced today that former Secretary of the ... board of directors. , , "I am excited ... battlefield and in emergency rooms throughout the US. I am ...
Cached Biology Technology:Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement 2Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors 2
(Date:10/18/2014)... for evaluation of suspected genetic conditions, whole-exome sequencing ... including detection of a number of rare genetic ... to a study appearing in JAMA . ... the American Society of Human Genetics annual meeting. ... regions of thousands of genes simultaneously using next-generation ...
(Date:10/17/2014)... from the University of Copenhagen have shown for the ... lungs of Cystic fibrosis patients, giving them the opportunity ... in chronic infections. , The study also discovered the ... (CF) patients was halted or slowed down by the ... all the oxygen and helped "suffocate" the bacteria, forcing ...
(Date:10/16/2014)... Washington land managers have a new synthesis of recent ... mixed-conifer (MMC) forests in the two states. , ... Eastern Oregon and Washington: A Synthesis of the Relevant ... general technical report published by the U.S. Forest Service,s ... a request from managers for a synthesis of the ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... paradox linking artificial sweeteners such as saccharin with ... on a sweet taste has guided researchers to ... taste. , Reporting in an advance ... Chemical Senses Center describe how certain artificial sweeteners, ...
... be a key to how bacteria that infect humans ... article in the January 20 issue of the journal ... found in dirt may be the key in identifying ... infect people, predicting future clinical problems, and testing new ...
... the Kuna Indians of Panama, an international team ... is, in part, responsible, for the heart-healthy benefits ... The researchers, who are from the University of ... and Harvard Medical School, hope the findings will ...
Cached Biology News:Sweet 'water taste' paradoxically predicts sweet taste inhibitors 2Researchers use dirt to stay one step ahead of antibiotic resistance 2Researchers use dirt to stay one step ahead of antibiotic resistance 3Heart-healthy compound in chocolate identified 2
... The Jouan MSC series of Class ... working conditions and certification to the ... regulation ensures that the cabinets cannot ... conditions. Natural lighting, low noise and ...
... HM-4000 Multidizer is designed with a variety ... rotating - all in one unit. Shake, ... independently operating compartments allow for hybridization and ... motion , The upper chamber uses ...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
... Sensitive Bio (for heat-labile and very volatile ... to specific applications of molecular biology and ... heat-labile samples. The RC systems can be ... and a wide selection of rotors (eliminating ...
Biology Products: